TDI-01 is under clinical development by Sino Biopharmaceutical and currently in Phase I for Pneumoconiosis. According to GlobalData, Phase I drugs for Pneumoconiosis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TDI-01 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TDI-01 overview

TDI-01 is under development for the treatment of non-alcoholic steatohepatitis (NASH), coronavirus disease 2019 (COVID-19) pneumonia, idiopathic pulmonary fibrosis, pulmonary fibrosis, chronic graft versus host disease, pneumoconiosis and Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) and unspecified rare CNS disorders. It acts by targeting Rho/Rho associated coiled-coil containing protein kinase 2 (ROCK2). It is administered through oral route.

Sino Biopharmaceutical overview

Sino Biopharmaceutical (Sino Biopharma), a subsidiary of Charoen Pokphand Group Co Ltd, is a research-oriented pharmaceutical company that develops, manufactures, and markets medicines, biopharmaceuticals, and Chinese medicines. It offers medicines for the treatment of hepatitis, cardio-cerebral diseases, cancer, orthopedic conditions, infectious diseases and respiratory and digestive diseases, among others. The company offers products in various dosage forms including large-volume injections, PVC-free soft bags for intravenous injections, small-volume injections, powdered medicines, granulated medicines, capsules, and tablets. It works in partnership with several domestic and foreign pharmaceutical companies to advance the development of its products. Sino Biopharma is headquartered in Wanchai, Hong Kong.

For a complete picture of TDI-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.